

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

CT Healthcare Trust PLC

ISIN: GB00BZCNLL95

This Key Information Document (KID) is issued and approved by Columbia Threadneedle Investment Business Limited. Authorised and regulated in the UK by the Financial Conduct Authority.

Date of Production: 14/04/2026

What is this product?

This product is a closed-end Investment Company incorporated in England and listed on the London Stock Exchange.

The strategy for the Company is a low net exposure, long/short equity strategy. Its investment objective is to provide absolute returns by investing in an actively managed portfolio of equities and derivatives with exposure to the global healthcare market.

The Company will seek to meet the investment objective by investing in a diversified portfolio of equity or equity-linked securities of companies which operate in or otherwise provide exposure to the global healthcare market including by taking short positions in stocks or markets that the investment manager considers to be over-valued or impaired, or where the investment manager considers it desirable for the purposes of hedging or risk control.

In particular, the Company may invest through equities, convertible securities, rights and warrants to subscribe for or purchase equity securities, index linked securities, contracts for difference (CFDs), equity linked and other debt securities, cash deposits, money market instruments, equity related securities, foreign currency exchange forward transactions and other interests including derivative instruments. Forward transactions and derivatives, including futures, options, swaps and contracts for difference, may be used to enhance portfolio performance as well as for efficient portfolio management and hedging.

The Company defines the "global healthcare market" in which it will invest as businesses operating in, having revenues predominantly arising from or otherwise having significant exposure to healthcare and healthcare-related sectors including, in particular, biotechnology, healthcare information technology, healthcare providers, healthcare services, life sciences, managed care providers, medical diagnostics, medical equipment, and pharmaceuticals.

The Trust is intended for Retail investors (with at least an Informed (experienced) level of investment knowledge), Professional Clients and Eligible Counterparties. Investors should be able to bear the risk of losing up to the full amount of their investment in the Trust.

This product has no fixed term or maturity and cannot be terminated without a shareholder vote.

What are the risks and what could I get in return?

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets.



The risk indicator assumes you keep the product for five years. The actual risk can vary significantly if you sell your shares at an early stage and you may get back less than you invested. You may not be able to sell your shares easily or you may have to sell at a price that significantly impacts on how much you get back.

We have classified this product as 5, which is the medium high risk class. This rates the potential losses from future performance at a medium high level. In periods when market conditions are poor, the value of your investment may fall and may impact the amount you get back in the long term.

In addition to market risk and risks introduced by way of regulation, this product also carries currency risk, effect of performance fees, effect of portfolio concentration, short selling risk, investment in derivatives, leverage risk, high volatility risk and share-price discount risk.

The value of your investment can go down as well as up. You may lose some or all of your investment. This product does not provide any protection from future market conditions and regulatory changes. There can be no assurances that the objective of the product will be achieved or that dividend distributions will continue to be made. The use of gearing can enhance returns to investors in a rising market, but if the market falls the losses may be greater.

Investment performance information

The main factors likely to affect future returns are the global economic outlook which will be a key driver for corporate earnings and interest rates which will influence stock valuations. Aside from these and other macro-drivers, stock selection will be the main driver of returns. A significant proportion of the Company's assets are expected to be denominated in overseas currencies, in particular the US dollar. Accordingly, the Sterling investment performance for investors may be affected by foreign exchange rates between Sterling and any overseas currencies in which investments are denominated, particularly the US dollar, rather than by investment performance alone. Gearing will also make a difference given the Company's policy to use this strategically.

What could affect my return positively?

Good stock selection, favorable exchange rate movements, as well as the impact of gearing impact returns positively.

What could affect my return negatively?

Poor stock selection, unfavorable exchange rate movements, as well as the impact of gearing can impact returns negatively.

If the investment trust is sold under severely adverse market conditions, you may increase the risk of receiving back significantly less than you invested.

What happens if the Company is unable to pay out?

The Company's shares are listed on the London Stock Exchange. Should the Company be liquidated, the amount you receive for your holding will be based on the value of assets available for distribution after all other liabilities, but before shareholders, have been paid. Shareholders in this company do not have the right to make a claim to the Financial Services Compensation Scheme in the event that the Company is unable to pay out.

What are the costs?

With the significant change in investment strategy the published Ongoing Charge within the Company's 30th November 2025 Annual Report is not considered to be representative of the future costs and charges of the Company. Therefore an estimated Ongoing Charge (expressed as a percentage of net assets) of 1.83% (excluding performance fee) has been calculated based on estimated future costs and net assets of the Company at the date of the appointment of Columbia Threadneedle Investment Business Limited as the new Manager of the Company. This calculation does not follow the AIC methodology due to less than 12 months information post transition being available.

For the avoidance of doubt this charge does not represent an additional cost to you in acquiring shares in the Company, it represents the operating costs borne by the Company that are reflected within the Company's Net Asset Value and ultimately in the Share Price you pay in acquiring the Company's shares. Depending on how you acquire or dispose of shares in the Company, you may be charged additional costs, these may include broker commission, platform fees, advisory fees and/or stamp duty. Details of any additional costs, together with the impact that all costs will have on your investment over time, will be provided by your chosen platform or adviser. This disclosure has been prepared with reference to the FCA's statement on 19 September 2024 that Investment Trusts are no longer required to follow the historical cost disclosures under the PRIIPs Regulation. It therefore does not seek to comply with the requirements of the UK PRIIPs Regulation in all respects.

A performance fee of 15% may be taken if the NAV rises above both the average three-month SONIA hurdle and its previous high-water mark, and is charged only on the portion of returns above these levels.

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

There is no minimum or maximum required period for investors to hold shares in this product, but the shares may not be suitable for investors intending to hold them for less than five years. Investors may sell their shares at any time without penalty through a broker, private investor plan administrator or adviser. The sale price will be determined at arms' length based on trading prices at the time on the London Stock Exchange and will not necessarily be equal to the net asset value per share of the CT Healthcare Trust PLC. The share price is updated regularly on the website www.ctinvest.co.uk/fundsandprices

Market values may go down as well as up over short and long periods and so investors should invest with a view to long term returns. The amount investors get back will be influenced by the market factors at the time of sale and by the charges levied by the broker/plan manager. If you sell your shares before the end of the recommended holding period you may increase the risk of receiving back less than you invested.

How can I complain?

If you have concerns about this product, please contact the Company Secretary by writing to the CT Healthcare Trust PLC, Cannon Place, 78 Cannon Street, London, EC4N 6AG, UK or by phone 020 7628 8000. Should you have a complaint about any transaction through your broker, plan administrator or adviser, you should contact that person or organisation directly.

As a shareholder of the CT Healthcare Trust PLC, you do not have a right to complain to the Financial Ombudsman Service (FOS) in the UK about the management of the CT Healthcare Trust PLC.

Other relevant information

You may obtain further information about the CT Healthcare Trust PLC from the website www.ctinvest.co.uk/fundsandprices including this document; the Investor Disclosure Document; and the latest share price. Alternatively, you may write to the Company Secretary, the CT Healthcare Trust PLC, at: Cannon Place, 78 Cannon Street, London, EC4N 6AG, UK.